...
首页> 外文期刊>Chinese Medicine >Jiangtang decoction ameliorate diabetic nephropathy through the regulation of PI3K/Akt-mediated NF-κB pathways in KK-Ay mice
【24h】

Jiangtang decoction ameliorate diabetic nephropathy through the regulation of PI3K/Akt-mediated NF-κB pathways in KK-Ay mice

机译:降糖汤通过调节PI3K / Akt介导的KK-Ay小鼠的糖尿病性肾病改善糖尿病

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Jiangtang decoction (JTD) is a China patented drug which contains Euphorbia humifusa Willd, Salvia miltiorrhiza Bunge, Astragalus mongholicus Bunge, Anemarrhena asphodeloides Bunge, and Coptis chinensis Franch. For decades, it has also been used clinically to treat diabetic nephropathy (DN) effectively; however, the associated mechanisms remain unknown. Thus, the present study aimed to examine the protective efficacy of JTD in DN and elucidate the underlying molecular mechanisms. Methods A diabetic model using KK-Ay mice received a daily administration of JTD for 12?weeks. Body weight, blood glucose, triglycerides (TGs), total cholesterol (TC), urea nitrogen (UN), creatinine (Cr), and microalbumin/urine creatinine (MA/UCREA) was measured every 4?weeks. Furthermore, on the day of the sacrifice, blood, urine, and kidneys were collected to assess renal function according to general parameters. Pathological staining was performed to evaluate the protective renal effect of JTD. In addition, the levels of inflammatory cytokines (tumor necrosis factor-α [TNF-α], interleukin [IL]-6 and intercellular adhesion molecule [ICAM]-1), insulin receptor substrate [IRS]-1, advanced glycation end products [AGEs], and receptor of glycation end products [RAGE] were assessed. Finally, the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway and involvement of nuclear factor-κB (NF-κB) was further analyzed. Results After 12?weeks of metformin and JTD administration, the mice exhibited a significant amelioration in glucose and lipid metabolism dysfunction, reduced morphological changes in the renal tissue, decreased urinary albumin excretion, and normalized creatinine clearance. JTD treatment also reduced the accumulation of AGEs and RAGE, up-regulated IRS-1, and increased the phosphorylation of both PI3K (p85) and Akt, indicating that the activation of the PI3K/Akt signaling pathway was involved. Additionally, JTD administration reduced the elevated levels of renal inflammatory mediators and decreased the phosphorylation of NF-κB p65. Conclusions These results demonstrate that JTD might reduce inflammation in DN through the PI3K/Akt and NF-κB signaling pathways.
机译:背景降糖汤(JTD)是一种中国专利药物,其中包含大戟,丹参,黄芪,黄连泻药和黄连。数十年来,它还被临床有效地用于治疗糖尿病性肾病(DN)。但是,相关的机制仍然未知。因此,本研究旨在检查JTD在DN中的保护作用,并阐明其潜在的分子机制。方法使用KK-Ay小鼠的糖尿病模型每天接受JTD给药12周。每4周测量一次体重,血糖,甘油三酸酯(TGs),总胆固醇(TC),尿素氮(UN),肌酐(Cr)和微量白蛋白/尿肌酐(MA / UCREA)。此外,在牺牲的当天,根据一般参数收集血液,尿液和肾脏以评估肾功能。进行病理染色以评估JTD的保护性肾脏作用。此外,炎症细胞因子(肿瘤坏死因子-α[TNF-α],白介素[IL] -6和细胞间粘附分子[ICAM] -1),胰岛素受体底物[IRS] -1,晚期糖基化终产物的水平[AGEs]和糖基化终产物的受体[RAGE]被评估。最后,进一步分析了磷酸肌醇3-激酶(PI3K)/蛋白激酶B(Akt)的信号传导途径和核因子-κB(NF-κB)的参与。结果二甲双胍和JTD给药12周后,小鼠的血糖和脂质代谢功能异常明显改善,肾脏组织形态变化减少,尿白蛋白排泄减少,肌酐清除率恢复正常。 JTD处理还减少了AGEs和RAGE的积累,上调了IRS-1,并增加了PI3K(p85)和Akt的磷酸化,表明PI3K / Akt信号通路的激活。此外,JTD给药降低了肾炎介质的升高水平,并降低了NF-κBp65的磷酸化。结论这些结果表明,JTD可能通过PI3K / Akt和NF-κB信号通路减少DN中的炎症。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号